Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 3, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 121,650 shares of Curis common stock to two new employees, with a grant date of October 3, 2022 (the “Q4 2022 Inducement Grants”). Each of the Q4 2022 Inducement Grants has an exercise price per share equal to the closing price of the Company’s common stock on October 3, 2022. Each stock option has a 10 year term and vests over four years, with 25% of the original number of sha(…) Read More »

Exit mobile version